Format

Send to

Choose Destination
PLoS One. 2017 Jun 20;12(6):e0178253. doi: 10.1371/journal.pone.0178253. eCollection 2017.

CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner.

Yan Z1,2, Zhao J2,3, Gan L2,4, Zhang Y2,3, Guo R2,4, Cao X5, Lau WB2, Ma X2,4, Wang Y2,4.

Author information

1
Department of Ophthalmology, The First Affiliated Hospital, Shanxi Medical University, Taiyuan, Shanxi, China.
2
Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, United States of America.
3
Department of Anesthesiology, The First Affiliated Hospital, Shanxi Medical University, Taiyuan, Shanxi, China.
4
Department of Physiology, Shanxi Medical University, Taiyuan, Shanxi, China.
5
Department of Orthopedics, The Second Affiliated Hospital, Shanxi Medical University, Taiyuan, Shanxi, China.

Abstract

OBJECTIVES:

Diabetic retinopathy (DR) is a severe complication of chronic diabetes. The C1q/TNF-related protein family (CTRPs) has been demonstrated to exert protective effects against obesity and atherosclerosis in animal studies. Heretofore, the association between circulating CTRPs and DR patients has been unexplored. In the current study, we attempt to define this association, as well as the effect of CTRPs upon DR pathophysiology.

DESIGN:

The present investigation is a case control study that enrolled control subjects and type 2 diabetes mellitus (T2DM) patients diagnosed with DR. Serum CTRPs and sVACM-1 were determined by ELISA.

RESULTS:

Serum CTRP3 and CTRP5 levels were markedly decreased in patients with T2DM compared to controls (p<0.05) and inversely associated with T2DM. Furthermore, mutivariate regression and ROC analysis revealed CTRP3 deficiency, not CTRP5, was associated with proliferative diabetic retinopathy (PDR). Spearman's rank correlation assay demonstrated an inverse association between CTRP3 and sVCAM-1. Finally, exogenous CTRP3 administration attenuated high glucose high lipid (HGHL)-induced VCAM-1 production in an AMPK-dependent manner in cultured human retinal microvascular endothelial cells (HRMECs).

CONCLUSION:

CTRP3 may serve as a novel biomarker for DR severity. CTRP3 may represent a future novel therapeutic against DR, a common ocular complication of diabetes.

PMID:
28632765
PMCID:
PMC5478095
DOI:
10.1371/journal.pone.0178253
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center